VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
RKTO
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
RKTORocket One Inc.
$0.32$9M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksRKTOBalance Sheet

Rocket One Inc. (RKTO) Balance Sheet

9Y historyFree accessUpdated daily

The firm's equity base has contracted to $4.2 million in 2026Q1, driven by the accumulation of $75.6 million in total retained losses.

Income StatementBalance SheetCash FlowRatios

RKTO Balance Sheet

Annual statement

RKTO Balance Sheet

Rocket One Inc. (RKTO) balance sheet — 9-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17
Total Current Assets6.86M6.86M7.64M10.15M6.73M10.58M4.78M2.64M501.65K1.23M
Cash & Short-Term Investments6.02M6.25M7.04M9.29M6.64M10.43M4.69M2.49M282.62K1.23M
Cash Only6.02M6.25M7.04M9.29M6.43M8.54M2.63M1.69M282.62K1.23M
Short-Term Investments0000209.32K1.89M2.06M803.66K00
Accounts Receivable4.52K046.77K0050K0000
Days Sales Outstanding11.79K---------
Inventory0000000000
Days Inventory Outstanding----------
Other Current Assets0248.54K046.77K00030.48K206.67K0
Total Non-Current Assets1.8M740.89K67.89K92.56K33K410K460K201.04K2.27K3.49K
Property, Plant & Equipment04.65K31.07K55.16K0001.04K2.27K3.49K
Fixed Asset Turnover0.03x---------
Goodwill590.79K000000000
Intangible Assets208.85K000000000
Long-Term Investments147.28K36.82K36.82K37.4K33K410K410K200K00
Other Non-Current Assets967.13K699.42K000050K000
Total Assets8.66M7.6M7.71M10.24M6.76M10.99M5.24M2.84M503.92K1.23M
Asset Turnover0.00x---------
Asset Growth %-67.63%-1.42%-24.7%51.54%-38.47%109.53%84.86%462.82%-59.16%-
Total Current Liabilities1.24M1.45M831.2K678.66K1.39M867.79K312.15K440.12K348.95K49.47K
Accounts Payable695.78K823.67K412.07K35.59K694.99K360.96K129.47K403.88K142.28K47.92K
Days Payables Outstanding-------4.66K1.84K93.04K
Short-Term Debt0000000000
Deferred Revenue (Current)0000000000
Other Current Liabilities0000000000
Current Ratio5.55x4.72x9.20x14.96x4.85x12.19x15.32x5.99x1.44x24.87x
Quick Ratio5.55x4.72x9.20x14.96x4.85x12.19x15.32x5.99x1.44x24.87x
Cash Conversion Cycle11.79K---------
Total Non-Current Liabilities002.71K26.33K250K235K285K0142.28K0
Long-Term Debt0000000000
Capital Lease Obligations002.71K26.33K000000
Deferred Tax Liabilities0000000000
Other Non-Current Liabilities0000250K235K285K000
Total Liabilities1.24M1.45M833.91K704.98K1.64M1.1M597.15K440.12K348.95K49.47K
Total Debt05.68K31.07K55.16K000000
Net Debt-6.02M-6.24M-7.01M-9.24M-6.43M-8.54M-2.63M-1.69M-282.62K-1.23M
Debt / Equity0.00x0.00x0.00x0.01x------
Debt / EBITDA-0.00x--0.21x------
Net Debt / EBITDA0.52x---35.43x------
Interest Coverage-----36.24x-----
Total Equity7.42M6.15M6.88M9.54M5.12M9.88M4.65M2.4M154.97K1.18M
Equity Growth %-100.17%-10.58%-27.88%86.23%-48.17%112.72%93.89%1446.16%-86.92%-
Book Value per Share0.300.451.082.804.2811.069.396.540.413.08
Total Shareholders' Equity7.42M6.15M6.88M9.54M5.12M9.88M4.65M2.4M154.97K1.18M
Common Stock2.49K1.55K8044351302.4K1.34K1.01K507470
Retained Earnings-82.09M-72.88M-60.41M-52.22M-45.1M-33.73M-19.41M-12.22M-4.51M-2.02M
Treasury Stock0000000000
Accumulated OCI9.6K10.83K9.06K27.26K22.01K17.59K-15.35K0-3100
Minority Interest0000000000

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Clinical trial funding shortfall

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Asset Base Erosion Signals Risk

As reported in financial statements, Hoth Therapeutics' total assets have contracted from $12.4 million in 2025Q1 to $5.6 million by 2026Q1, reflecting a consistent depletion of resources that underscores the firm's ongoing struggle to maintain a stable capital base while funding its clinical development pipeline.

The steady decline in total assets suggests that the company is consuming its capital reserves faster than it can replenish them through financing or milestone-based inflows. This downward trajectory warrants close monitoring, as it indicates that the firm's current business model is not yet self-sustaining and remains entirely dependent on external capital injections.

Diminishing Runway Threatens Operational Continuity

Based on reported figures, the company's cash position has dwindled to $4.0 million as of 2026Q1, a significant reduction from the $11.3 million held in 2025Q1, which suggests that the firm's liquidity buffer is rapidly eroding in the face of persistent, high-cost clinical research obligations.

While the current ratio remains above 3.0, the absolute decline in cash reserves is the more critical metric for a pre-revenue entity. This trend implies that management may soon face a binary choice between aggressive equity dilution or the potential suspension of key clinical programs to preserve remaining capital.

Equity Quality Diluted by Losses

According to recent SEC filings, the company's equity base has shrunk to $4.2 million in 2026Q1 from a peak of $11.5 million in 2025Q1, a trend primarily driven by the accumulation of retained losses that now total approximately $75.6 million as of the most recent quarter.

The persistent growth in negative retained earnings highlights the high cost of the company's licensing-heavy strategy and the lack of offsetting commercial revenue. Investors should interpret this erosion of equity as a signal that the firm's value is increasingly tied to speculative future clinical outcomes rather than tangible book value.

Hidden Risks in Asset Composition

As indicated by the company's balance sheet, the absence of capitalized intangible assets or significant PPE suggests that the firm's primary value is not reflected in traditional accounting metrics, potentially masking the true risk of its reliance on external academic intellectual property agreements.

Because the company does not capitalize its research licenses, the balance sheet fails to capture the long-term financial commitments or potential impairment risks associated with these academic partnerships. This creates a distortion where the firm appears asset-light, yet it remains burdened by significant, non-disclosed contractual obligations that could trigger cash outflows.

RKTO — Frequently Asked Questions

Quick answers to the most common questions about buying RKTO stock.

What are the total assets of Rocket One Inc. (RKTO)?

As of 2025, Rocket One Inc. (RKTO) had total assets of $7.6M including $6.9M in current assets.

How much debt does Rocket One Inc. (RKTO) have?

Rocket One Inc. (RKTO) carries total debt of $0.0M, offset by $6.2M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of Rocket One Inc.?

Rocket One Inc. (RKTO) has total shareholders' equity (book value) of $6.2M ($0.45 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is Rocket One Inc.'s current ratio and liquidity?

Rocket One Inc. (RKTO) reported a current ratio of 4.72x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.